KOL | Timothy J WiltMinneapolis VA Evidence Synthesis Program, Center for Care Delivery and Outcomes Research, and University of Minnesota School of Medicine, Minneapolis, Minnesota (W.D., ... |
KOL Resume for Timothy J Wilt
| Year | |
|---|---|
| 2022 | Minneapolis VA Evidence Synthesis Program, Center for Care Delivery and Outcomes Research, and University of Minnesota School of Medicine, Minneapolis, Minnesota (W.D., T.J.W.) |
| 2021 | Veterans Affairs Health Services Research and Development Center for Care Delivery and Outcomes Research, Minneapolis Veterans Affairs Healthcare System, 1 Veterans Drive, Mail Code#152, Minneapolis, Minneapolis, MN 55417 United States; Department of Medicine, University of Minnesota, MN 55455 United States; Department of Public Health, University of Minnesota, Minneapolis, MN 55455 United States. Minneapolis VA Health Care System and University of Minnesota School of Medicine, Minneapolis, Minnesota (A.S.K., W.D., T.J.W.) |
| 2020 | UCSD School of Medicine, La Jolla, California. Center for Care Delivery and Outcomes Research, VAHSRD Minneapolis VA Health Care System, Minneapolis, MN, USA Minneapolis VA Health Care System and University of Minnesota, Minneapolis, Minnesota (H.A.F., J.R.M., L.S.H., B.C.T., T.J.W.). |
| 2019 | University of Minnesota and Minneapolis VA Health Care System, Minneapolis, Minnesota (H.A.F., R.M., K.E.E., K.U., B.C.T., T.J.W.). Minneapolis VA Center for Care Delivery and Outcomes Research (CCDOR) American Urological Association Education and Research, Inc., Linthicum, Maryland. |
| 2018 | Minneapolis Veterans Affairs Health Care System Evidence-based Synthesis Program Site and Center for Chronic Disease Outcomes Research and University of Minnesota, Minneapolis, Minnesota (T.J.W.). |
| 2017 | VA HSR&D Center for Chronic Disease Outcomes Research, Minneapolis VA Healthcare System, 1 Veterans Drive (152), Minneapolis, MN 55417 USA From the American College of Physicians and Penn Health System, Philadelphia, Pennsylvania; Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota; and Yale School of Medicine, New Haven, Connecticut. Minneapolis Veterans Affairs Health Care System, Minneapolis, MN |
| 2016 | Center for Chronic Disease Outcomes Research (CCDOR), Minneapolis Veterans Affairs Health Care System, Minneapolis, MN, USA Department of Medicine, University of Minnesota, Minneapolis, Minnesota |
| 2015 | Department of Medicine, University of Minnesota, Minneapolis, MN From Erasmus MC University Medical Center, Rotterdam, the Netherlands; University of Minnesota School of Medicine, Minneapolis, Minnesota; and Fred Hutchinson Cancer Research Center, Seattle, Washington. University of Minnesota, Minneapolis, USA |
| 2014 | Minneapolis VA Health Care System, One Veterans Drive, Minneapolis, MN 55417, USA |
Timothy J Wilt: Influence Statistics
| Concept | World rank |
|---|---|
| bph urinary | #1 |
| invasive disease gemcitabine | #1 |
| correct responses controls | #1 |
| betasitosterol bph | #1 |
| nonmalignant enlargement | #1 |
| repens treatment | #1 |
| cohort urologist | #1 |
| postextubation management cot | #1 |
| patient knowledge preferences | #1 |
| measures bph symptoms | #1 |
| 2—management | #1 |
| rezūm aquablation | #1 |
| paraprost placebo | #1 |
| tumt adverse effects | #1 |
| evidence newer drugs | #1 |
| paraprost | #1 |
| 5 years 95 | #1 |
| versus observation | #1 |
| general specialized | #1 |
| surgeon radical | #1 |
| initiation timing frequency | #1 |
| handsearching references | #1 |
| cernilton | #1 |
| small reduction proportion | #1 |
| hfno cot | #1 |
| acp pocus | #1 |
| prevalence rates trends | #1 |
| treatment luts | #1 |
| outcome measure effects | #1 |
| phytotherapies serenoa repens | #1 |
| male patients chd | #1 |
| survival 5 years | #1 |
| asymptomatic averagerisk adults | #1 |
| aes newer drugs | #1 |
| survival allocation | #1 |
| life absolute effects | #1 |
| treatment efficacy 19 | #1 |
| update alert remdesivir | #1 |
| contact lasers | #1 |
| measures patient knowledge | #1 |
| bcg tumour recurrence | #1 |
| treating symptomatic | #1 |
| bph wmd | #1 |
| tumt symptomatic bph | #1 |
| placebo pooled improvement | #1 |
| interferonalfa randomized studies | #1 |
| hyperplasia randomized | #1 |
| microwave thermotherapy turp | #1 |
| abs evidence | #1 |
| bcg metaanalysis | #1 |
Open the FULL List in Excel | |
Prominent publications by Timothy J Wilt
BACKGROUND: Intravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer is a well established treatment for preventing or delaying tumour recurrence following tumour resection. However, up to 70% of patients may fail and new intravesical agents with improved effectiveness are needed. Gemcitabine is a relatively new anticancer drug that has shown activity against bladder cancer.
OBJECTIVES: To evaluate the effectiveness and toxicity of intravesical gemcitabine in ...
| Known for Intravesical Gemcitabine | Bladder Cancer | Muscle Invasive | Antineoplastic Antimetabolites | Immunologic Administration |
Intravesical gemcitabine therapy for non‐muscle invasive bladder cancer (NMIBC): a systematic review
[ PUBLICATION ]
• Intravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer is a well-established treatment for preventing or delaying tumour recurrence after tumour resection. However, up to 70% of patients may fail and new intravesical agents with improved effectiveness are needed. Gemcitabine is a relatively new anticancer drug that has shown activity against bladder cancer. • To systematically review the literature on the effectiveness and toxicity of intravesical ...
| Known for Intravesical Gemcitabine | Bladder Cancer | Patients Nmibc | Muscle Invasive | Immunologic Administration |
BACKGROUND: Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH is common. The extract of the berry of the American saw palmetto, or dwarf palm plant, Serenoa repens (also known by its botanical name of Sabal serrulatum), is one of several phytotherapeutic agents available for the ...
| Known for Serenoa Repens | Benign Prostatic Hyperplasia | Treatment Bph | Placebo Interventions | Outcome Measure |
BACKGROUND: Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. Ninety percent of men with prostate cancer are over aged 60 years, diagnosed by early detection with the prostate specific antigen (PSA) blood test and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting surgery to remove the prostate gland (radical ...
| Known for Prostate Cancer | Controlled Trial | Clinically Localized | Versus Observation | Prostatic Neoplasms |
BACKGROUND: Benign prostatic hyperplasia (BPH), nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH has been growing steadily. The extract of the American saw palmetto or dwarf palm plant, Serenoa repens (also known by its botanical name of Sabal serrulatum), is one of the several phytotherapeutic agents available for the ...
| Known for Serenoa Repens | Benign Prostatic Hyperplasia | Treatment Bph | Urinary Symptoms | Outcome Measure |
BACKGROUND: Transurethral resection of the prostate (TURP) has been the gold-standard treatment for alleviating urinary symptoms and improving urinary flow in men with symptomatic benign prostatic hyperplasia (BPH). However, the morbidity of TURP approaches 20%, and less invasive techniques have been developed for treating BPH. Preliminary data suggest that microwave thermotherapy, which delivers microwave energy to produce coagulation necrosis in prostatic tissue, is a safe, effective ...
| Known for Microwave Thermotherapy | Prostate Turp | Prostatic Hyperplasia | Urinary Flow | Transurethral Resection |
Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review
[ PUBLICATION ]
What's known on the subject? and What does the study add? For the past 30 years Serenoa repens has become a widely used phytotherapy in the USA and in Europe, mostly because of positive comparisons to α-blockers and 5α-reductase inhibitors. During the last 4 years we have seen two very high quality trials comparing Serenoa repens to placebo and up to 72 weeks' duration. These trials found Serenoa repens no better than placebo, even (in one trial) at escalating doses.
OBJECTIVE: • To ...
| Known for Serenoa Repens | Benign Prostatic Hyperplasia | Placebo Luts | Lower Urinary | Tract Symptoms |
Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer
[ PUBLICATION ]
BACKGROUND: Tumour recurrence following transurethral resection (TUR) for Ta and T1 bladder cancer is a major clinical problem. Intravesical administration of mitomycin C (MMC) or bacillus Calmette-Guerin (BCG) has proven prophylactic activity but both are associated with local and systemic side-effects. A systematic review was carried out to compare the efficacy of these two agents.
OBJECTIVES: To undertake a systematic review and meta-analysis comparing intravesical mitomycin C and ...
| Known for Mmc Bcg | Tumour Recurrence | Bladder Cancer | Intravesical Antibiotics | Hazard Ratio |
Neo‐adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
[ PUBLICATION ]
BACKGROUND: Hormone therapy for early prostate cancer has demonstrated an improvement in clinical and pathological variables, but not always an improvement in overall survival. We performed a systematic review of both adjuvant and neo-adjuvant hormone therapy combined with surgery or radiotherapy in localised or locally advanced prostate cancer.
OBJECTIVES: The objective of this review was to undertake a systematic review and, if possible, a meta-analysis of neo-adjuvant and adjuvant ...
| Known for Hormone Therapy | Prostate Cancer | 5 Years | Adjuvant Disease | Local Control |
OBJECTIVE: To assess, in a systematic review and meta-analysis, the relative effectiveness of intravesical mitomycin C and bacillus Calmette-Guérin (BCG) for tumour recurrence, disease progression and overall survival in patients with medium- to high-risk Ta and T1 bladder cancer.
METHODS: The major medical databases were searched comprehensively up to June 2003, and relevant journals hand-searched for randomized controlled trials, in any language, that compared intravesical mitomycin C ...
| Known for Tumour Recurrence | Mitomycin Bcg | Bladder Cancer | Immunologic Administration | Intravesical Antibiotics |
Key People For Prostate Cancer
Timothy J Wilt:Expert Impact
Concepts for whichTimothy J Wilthas direct influence:Prostate cancer, Benign prostatic hyperplasia, Serenoa repens, Radical prostatectomy, Urinary incontinence, Prostatic hyperplasia, Randomised trials, Transurethral resection.
Timothy J Wilt:KOL impact
Concepts related to the work of other authors for whichfor which Timothy J Wilt has influence:Prostate cancer, Erectile dysfunction, Benign prostatic hyperplasia, Active surveillance, Cardiovascular disease, Metabolic syndrome, United states.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |